Cosunter(SZ:300436) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-07-31 23:22Core Viewpoint - The stock of Fujian Guangshengtang Pharmaceutical Co., Ltd. has experienced significant price fluctuations, with a cumulative increase of over 30% from July 29 to July 31, 2025, despite the company's continuous losses over the past three years and the uncertainty surrounding its innovative drug development [2][4][6]. Group 1: Stock Performance and Market Reaction - The company's stock price has deviated significantly, with a cumulative increase of over 30% during the specified trading days, indicating abnormal trading activity [2][4]. - As of July 30, 2025, the company's latest price-to-book ratio is 46.58, which is substantially higher than the industry average of 3.17 for the pharmaceutical manufacturing sector [2]. Group 2: Financial Performance - The company has reported continuous losses over the last three years and the first quarter of 2025, with net profits attributed to shareholders being -127.40 million, -348.59 million, -156.30 million, and -28.49 million respectively [2][6]. Group 3: Drug Development Updates - The company announced the successful enrollment of the first subject in the Phase III clinical trial for its innovative hepatitis B treatment, GST-HG141, on July 26, 2025. However, this does not guarantee market approval and is not expected to have a significant impact on the company's financial performance in the short term [3][5]. - The drug development process is lengthy and costly, with high risks associated with technology, approval, and policy factors, leading to uncertainties regarding the potential for market approval [3][6].